Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Advanced gastric carcinoma is a highly aggressive malignancy with significant global impact, accounting for over 1.09 million new cases in 2022 and ranking as the fifth most common cancer worldwide. Men are more frequently affected, and incidence rises with age. The advanced gastric carcinoma pipeline analysis by Expert Market Research highlights emerging therapies, including targeted agents, immunotherapies, and antibody-drug conjugates. These innovative treatments aim to address unmet clinical needs, improve survival outcomes, and provide new options for patients with advanced disease.
-
Major companies involved in the advanced gastric carcinoma pipeline analysis include Plexium, Inc., NiKang Therapeutics, Inc., and others.
-
Leading drugs currently in the pipeline include MRG007, SH009, and others.
-
The advanced gastric carcinoma pipeline is driven by rising adoption of targeted therapies and immuno-oncology agents, including HER2 inhibitors and PD-1/PD-L1 checkpoint blockers. Precision medicine initiatives, biomarker-driven patient selection, and increasing global clinical trial activity are accelerating development, creating unique growth opportunities beyond conventional chemotherapy-based approaches.
Report Coverage
The Advanced Gastric Carcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into advanced gastric carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced gastric carcinoma. The advanced gastric carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced gastric carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with advanced gastric carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced gastric carcinoma.
Read more about this report - Request a Free Sample
Advanced Gastric Carcinoma Pipeline Outlook
Advanced gastric carcinoma remains a challenging disease, traditionally managed with combination chemotherapy and targeted agents following diagnosis.
Advanced gastric carcinoma treatment continues to face challenges, as modest survival gains from conventional regimens leave unmet needs in later-line therapy, driving robust global pipeline activity. For instance, in March 2025, the FDA approved pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1). This milestone underscores the growing momentum in precision oncology and immuno-targeted therapies, highlighting ongoing pipeline innovation and the potential to improve outcomes for patients with advanced disease worldwide.
Advanced Gastric Carcinoma Epidemiology
Globally, gastric cancer remains a major health burden, with an estimated 1.09-1.10 million new cases in 2022, ranking as the world’s fifth most common cancer. Incidence and mortality rates vary widely by region, with rates highest in East Asia and Eastern Europe and lowest in Africa and North America. Men are consistently more affected than women, and incidence increases with age. Long‑term projections indicate a growing burden from demographic shifts and risk factors like Helicobacter pylori infection and diet, particularly in high‑incidence countries such as China, Japan, and South Korea.
Advanced Gastric Carcinoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of advanced gastric carcinoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The advanced gastric carcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymer
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Topical
- Others
Advanced Gastric Carcinoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total advanced gastric carcinoma clinical trials. The landscape includes 42% Phase 1, 45% Phase 2, 12% Phase 3. This distribution highlights a strong focus on mid-stage clinical development, reflecting the growing momentum of promising therapeutic candidates progressing through the pipeline.
Advanced Gastric Carcinoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the advanced gastric carcinoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The advanced gastric carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced gastric carcinoma. In November 2023, the FDA approved pembrolizumab (Keytruda) with fluoropyrimidine‑ and platinum‑containing chemotherapy for first‑line treatment of adults with locally advanced unresectable or metastatic HER2‑negative gastric or gastroesophageal junction adenocarcinoma, demonstrating improved survival outcomes.
Advanced Gastric Carcinoma Clinical Trials – Key Players
The EMR report for the advanced gastric carcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed advanced gastric carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in advanced gastric carcinoma clinical trials:
- Jiangsu HengRui Medicine Co., Ltd.
- Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
- Beijing Tide Pharmaceutical Co., Ltd.
- FutureGen Biopharmaceutical (Beijing) Co., Ltd.
- Bristol-Myers Squibb
- TORL Biotherapeutics, LLC
- Amgen
- Astellas Pharma Global Development, Inc.
- Plexium, Inc.
- NiKang Therapeutics, Inc.
Advanced Gastric Carcinoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for advanced gastric carcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced gastric carcinoma drug candidates.
Drug: HER3-DXd
HER3-DXd is an antibody-drug conjugate (ADC) developed by Daiichi Sankyo, designed to target the HER3 receptor, which is overexpressed in several solid tumors, including gastric carcinoma. The ADC delivers a cytotoxic payload directly to HER3-expressing tumor cells, thereby minimizing off-target effects. Clinical studies are evaluating its efficacy in advanced solid tumors. Daiichi Sankyo, known for pioneering ADCs, continues to expand HER3-DXd development globally, leveraging its expertise in targeted oncology therapeutics to accelerate clinical translation and patient access.
Drug: SHR1701
SHR1701 is a bifunctional fusion protein developed by Hengrui Medicine, combining PD-1 inhibition with TGF-β blockade to enhance antitumor immune response. By simultaneously blocking immune checkpoints and immunosuppressive signaling, SHR1701 aims to restore T-cell activity against tumors, particularly in advanced gastric carcinoma. Hengrui Medicine is actively conducting multiple clinical trials across China and internationally, positioning SHR1701 as a promising next-generation immunotherapy in the competitive checkpoint inhibitor landscape.
Drug: PLX-61639
PLX-61639 is a small-molecule kinase inhibitor under development by Plexium, Inc., targeting specific oncogenic signaling pathways implicated in advanced gastric carcinoma and other solid tumors. It inhibits aberrant kinase activity to suppress tumor growth and proliferation. Plexium, Inc. is leveraging its precision oncology platform, is conducting early-phase clinical trials to evaluate PLX-61639’s safety and efficacy, aiming to establish it as a novel therapeutic option for patients with refractory or advanced malignancies.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Advanced Gastric Carcinoma Pipeline Insight Report
- Which companies/institutions are leading advanced gastric carcinoma drug development?
- Which company is leading the advanced gastric carcinoma pipeline development activities?
- What is the current advanced gastric carcinoma commercial assessment?
- What are the opportunities and challenges present in the advanced gastric carcinoma pipeline landscape?
- What is the efficacy and safety profile of advanced gastric carcinoma pipeline drugs?
- Which company is conducting major trials for advanced gastric carcinoma drugs?
- Which companies/institutions are involved in advanced gastric carcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in advanced gastric carcinoma?
Reasons To Buy This Report
The Advanced Gastric Carcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for advanced gastric carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into advanced gastric carcinoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share